The UK medicine regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has launched a new service called AdvanceGxP.
Science, Innovation and Investment Minister Chris McDonald MP announced the Advance GxP service during his closing keynote at the DIA-MHRA Summit in London, part of London Life Sciences Week.
What is MHRA's AdvanceGxP for?
The new service is directed at companies developing new technologies to make medicines, including personalised treatments made at or near hospitals and clinics, manufacturing in space, and the use of AI, robotics and automation.
McDonald explained that the new service is designed to make navigating the regulators a smoother process, "preventing delays and ensuring that patients get to see the benefits of scientific advances as soon as possible".
These innovators are set to receive earlier practical support from the MHRA to make sure their technology's novelty slows the process down as little as possible. This support means these teams can ask regulatory and quality questions earlier in the process, reducing the risk of avoidable redesign and delays.
MHRA Chief Executive, Lawrence Tallon, reinforced that giving developers practical support early can solve problems before they happen. "[This will] make it easier for promising new approaches to grow and scale here."
Who is funding the new initiative?
The MHRA has secured funding from the Office for Life Sciences (OLS) to develop and test AdvanceGxP.
The funding will enable the MHRA to recruit a new specialist team and develop the service, including how organisations will access it, which technologies and projects will be prioritised, and how it will connect with existing MHRA support.
Initial capacity will be limited while the approach is developed and tested, with this work to inform how the service could operate sustainably and potentially broaden in the future.
Keeping the UK competitive in the global pharma scene
The approach is intended to support patient access to new treatments and strengthen UK manufacturing, supporting the Government’s Life Sciences Sector Plan and wider Industrial Strategy.
OLS Director, Kenan Poleo, said: “As competition for life sciences investment intensifies, the UK’s regulatory environment can be a powerful competitive advantage. By helping regulation keep pace with innovation, AdvanceGxP will give companies greater confidence to develop and manufacture transformative new technologies here in the UK.”
By helping regulation keep pace with innovation, AdvanceGxP will give companies greater confidence to develop and manufacture transformative new technologies here in the UK
New technologies are changing how and where medicines are made, from personalised treatments made at or near hospitals and clinics to manufacturing in space and the use of AI, robotics and automation. These advances can create questions about how established Good Practice standards for medicines manufacturing apply.
AdvanceGxP is designed to offer developers earlier access to specialist expertise to address these questions, helping avoid preventable redesign and delays later in development.
Advances can create questions about how established Good Practice standards for medicines manufacturing apply
AdvanceGxP will sit alongside wider MHRA work to give innovators earlier, more joined-up support for advanced manufacturing, helping create the conditions for promising ideas to be developed and manufactured in the UK and reach patients sooner.
This direction is reflected in the recently launched MHRA Strategy to 2030, which sets out a greater focus on early engagement and working across the health and life sciences system to support innovation, growth and patient access, and wider government ambitions to strengthen life sciences and advanced manufacturing in the UK.
Top image: Science, Innovation and Investment Minister Chris McDonald MP announcing the Advance GxP service during his closing keynote at the DIA-MHRA Summit, London. Image credit: UK Government